Jan 10, 2020 / 01:30PM GMT
Operator
Welcome to the Revance Therapeutics call discussing the company's exclusive U.S. distribution agreement for TEOXANE's line of FDA-approved dermal fillers. (Operator Instructions) As a reminder, this conference is being recorded today, January 10, 2020.
I would now like to turn the conference over to Jeanie Herbert, Senior Director of Investor Relations. Please go ahead.
Jeanie D. Herbert - Revance Therapeutics, Inc. - Senior Director of IR & Corporate Communications
Thank you, Kevin. With me on today's call from Revance Therapeutics is President and Chief Executive Officer, Mark Foley; Chief Financial Officer, Toby Schilke; Chief Commercial Officer, Aesthetics and Therapeutics, Dustin Sjuts; and Vice President of Medical Affairs, Aesthetics and Therapeutics, Conor Gallagher.
This morning, Revance Therapeutics announced a transformative aesthetics portfolio transaction with TEOXANE SA for the exclusive U.S. distribution rights of TEOXANE's RHA range of FDA-approved dermal fillers. If you have not received this news release and would like to
Revance Therapeutics, Inc. - Special Call Transcript
Jan 10, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers